Detail explain of ra vs os vs reactive arthritis vs gout vs pseudo gout
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from the textbooks. Let me compile a detailed, well-organized comparison.
Rheumatoid Arthritis vs. Osteoarthritis vs. Reactive Arthritis vs. Gout vs. Pseudogout
1. Rheumatoid Arthritis (RA)
Definition & Pathogenesis
RA is a chronic autoimmune inflammatory disease primarily attacking synovial joints but capable of involving virtually any organ. The trigger is CD4+ T cell activation against joint antigens (particularly citrullinated proteins). Key mediators:
- TNF, IL-1, IL-6 → recruit leukocytes, stimulate synoviocyte-derived proteases → cartilage destruction
- IL-17 (Th17 cells) → recruits neutrophils/monocytes
- RANKL on activated T cells → osteoclast activation → bone erosion
- Anti-citrullinated peptide antibodies (ACPA/anti-CCP) — present in ~70% of patients; highly specific
- Rheumatoid factor (RF) — IgM/IgA autoantibody against IgG Fc — present in ~80%; not specific
The synovium undergoes pannus formation (hyperplastic, invasive synovial tissue) that erodes cartilage and bone.
Epidemiology
- Prevalence: ~1–2% of adults
- Female:male ratio 3:1
- Peak onset: 20–50 years
- HLA-DR4 strongly associated (especially ACPA-positive RA)
Clinical Features
| Feature | Details |
|---|---|
| Joint pattern | Symmetric polyarthritis — MCPs, PIPs, wrists, MTPs; spares DIPs |
| Morning stiffness | ≥1 hour (hallmark) |
| Systemic symptoms | Fatigue, fever, weight loss |
| Extraarticular | Rheumatoid nodules, scleritis, pleuritis, pericarditis, vasculitis, Felty syndrome |
| Hand deformities | Swan-neck, boutonnière, ulnar drift, Z-thumb |
ACR 1987 Diagnostic Criteria (4 of 7 required, ≥6 weeks)
- Morning stiffness ≥1 hour
- Arthritis of ≥3 joint areas
- Arthritis of hand joints (wrist, MCP, or PIP)
- Symmetric arthritis
- Rheumatoid nodules
- Serum RF positive
- Radiographic erosions/periarticular osteopenia
Labs & Imaging
- ↑ ESR, ↑ CRP, normocytic anemia
- RF +ve (~80%), anti-CCP +ve (~70%) — anti-CCP more specific
- Synovial fluid: inflammatory (WBC >2,000/mm³, neutrophil predominance), no crystals
- X-ray: juxta-articular osteopenia → marginal erosions → joint space narrowing
Treatment
- NSAIDs — symptomatic relief
- DMARDs — cornerstone; methotrexate (first-line), hydroxychloroquine, sulfasalazine, leflunomide
- Biologics — anti-TNF (etanercept, adalimumab, infliximab), anti-IL-6 (tocilizumab), abatacept, rituximab
- JAK inhibitors — tofacitinib, upadacitinib, baricitinib
- Treat-to-target: goal is remission or low disease activity; early aggressive therapy prevents erosions
2. Osteoarthritis (OA)
Definition & Pathogenesis
OA is a degenerative joint disease — the most common joint disorder. It is primarily a failure of articular cartilage homeostasis where matrix breakdown (via matrix metalloproteinases and aggrecanases) exceeds synthesis. Inflammation is minimal and secondary, unlike RA. Locally produced IL-1 and TNF from chondrocytes may perpetuate degradation.
Epidemiology
- Most common arthritis; increases sharply with age
- Risk factors: obesity, prior joint injury, repetitive mechanical stress, female sex (postmenopause), genetics
Clinical Features
| Feature | Details |
|---|---|
| Joint pattern | Asymmetric (or bilateral weight-bearing); DIPs, PIPs, 1st CMC, hips, knees, lumbar/cervical spine |
| Pain character | Use-related pain, worse at end of day; relieved by rest |
| Morning stiffness | <30 minutes |
| Synovial fluid | Non-inflammatory (<2,000 WBC/mm³) |
| Bony changes | Heberden's nodes (DIP), Bouchard's nodes (PIP) |
Imaging
- Joint space narrowing (asymmetric, weight-bearing zones)
- Subchondral sclerosis
- Osteophytes (bone spurs)
- Subchondral cysts
- No erosions (unlike RA)
- Histology: fibrillation of articular cartilage → eburnation (exposed, polished bone)
Treatment
- Weight loss, physical therapy, exercise
- NSAIDs/acetaminophen (topical diclofenac preferred in elderly)
- Intra-articular corticosteroids or hyaluronic acid
- Joint replacement for end-stage disease
3. Reactive Arthritis (ReA)
Definition & Pathogenesis
Reactive arthritis is an aseptic inflammatory arthritis occurring 1–3 weeks after an extra-articular infection — classically genitourinary (GU) or gastrointestinal (GI). The joint is not directly infected; rather, the immune response to distant infection triggers synovitis. Bacterial antigens (and in Chlamydia ReA, possibly viable organisms in an altered metabolic state) have been identified in joint tissues.
Classic triggering organisms:
- GI tract: Salmonella typhimurium, Yersinia enterocolitica, Shigella flexneri, Campylobacter jejuni
- GU tract: Chlamydia trachomatis (most common)
HLA-B27: Present in 50–80% of patients — confers risk for arthritis onset, axial involvement, and chronicity. In epidemics, ReA develops in 2–7% of infected individuals but up to 20% of HLA-B27+ individuals.
Dactylitis in ReA results from inflammation of the joint capsule, entheses, periarticular structures, and periosteal bone simultaneously.
Epidemiology
- Predominantly young men (20–40 years)
- Formerly "Reiter's syndrome" (urethritis + conjunctivitis + arthritis triad) — term now discouraged
- Classified as a seronegative spondyloarthropathy (RF negative, HLA-B27 positive)
Clinical Features
| Feature | Details |
|---|---|
| Joint pattern | Asymmetric oligoarthritis, predominantly lower extremity large joints (knees, ankles) |
| Axial involvement | Sacroiliitis (asymmetric), non-marginal syndesmophytes |
| Classic triad | Urethritis / cervicitis + conjunctivitis/uveitis + arthritis |
| Skin/mucous membranes | Keratoderma blennorrhagicum (psoriasiform lesions on soles), circinate balanitis, painless oral ulcers |
| Dactylitis | "Sausage digits" — diffuse finger/toe swelling |
| Enthesitis | Achilles tendon, plantar fascia |
Labs
- RF negative, ANA negative
- HLA-B27 positive (50–80%)
- ↑ ESR/CRP; synovial fluid inflammatory, no crystals, cultures negative
- Urethral/cervical/stool cultures, Chlamydia PCR to confirm triggering infection
Treatment
- Treat underlying infection: Chlamydia → doxycycline or azithromycin + rifampicin for 6 months
- NSAIDs — first-line for joint symptoms
- Intra-articular corticosteroids
- Sulfasalazine if started within 3 months of onset
- Anti-TNF biologics for chronic HLA-B27+ spondyloarthritis (though ~50% resolve within 6 months)
4. Gout
Definition & Pathogenesis
Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposition in joints and soft tissues, secondary to sustained hyperuricemia. Uric acid is the terminal breakdown product of purines (xanthine oxidase converts hypoxanthine → xanthine → uric acid).
Causes of hyperuricemia:
- Underexcretion (90%): genetic variants, renal disease, diuretics, cyclosporine, low-dose aspirin
- Overproduction (10%): enzyme defects (Lesch-Nyhan), myeloproliferative disease, tumor lysis
Acute attack mechanism: MSU crystals activate the NLRP3 inflammasome → IL-1β release → neutrophil recruitment → intense acute inflammation.
Epidemiology
- Male:female ~7–9:1 (premenopausal women protected by estrogen promoting uric acid excretion)
- Postmenopausal women susceptible
- Peak age: men 40–60 years
- Strong associations: obesity, alcohol (ethanol blocks renal urate excretion), high-purine diet, diuretics, renal disease
Clinical Stages
- Asymptomatic hyperuricemia — uric acid elevated but no symptoms; not treated
- Acute gouty arthritis — sudden, severe monoarthritis; typically 1st MTP joint (podagra, 50% of first attacks); resolves in days-weeks even untreated
- Intercritical gout — asymptomatic interval between attacks; crystals still present
- Chronic tophaceous gout — tophi (urate crystal deposits) in joints, cartilage, soft tissue, tendon; can mimic RA
Clinical Features
| Feature | Details |
|---|---|
| Joints | 1st MTP (podagra) #1, then heel, ankle, knee, midtarsal, olecranon bursa |
| Attack character | Excruciating pain, swelling, erythema, warmth; often nocturnal onset; exquisite tenderness |
| Tophi | Ears, olecranon, Achilles, finger joints — can be confused with rheumatoid nodules |
| Women/elderly | Often polyarticular, may mimic RA |
Diagnosis
- Serum uric acid >8 mg/dL (men), >7 mg/dL (women) — helpful but not diagnostic; can be normal during acute attack
- Synovial fluid — definitive: needle-shaped, negatively birefringent crystals (yellow when parallel to polarizer axis)
- WBC 20,000–100,000/mm³ during acute attack (neutrophilic)
- X-ray chronic gout: "punched-out" erosions with overhanging edges, tophi; unlike RA — no periarticular osteopenia
Treatment
Acute attack:
- NSAIDs — indomethacin or any NSAID at maximum dose × 2 days then taper (first-line)
- Colchicine — 0.5–0.6 mg × 2 tabs initially, then 0.5–1 mg/hour until relief or GI toxicity or 6 mg max; second-line
- Corticosteroids — oral prednisone (0.5 mg/kg), intra-articular (triamcinolone), or ACTH when NSAIDs/colchicine contraindicated
Prophylaxis & urate-lowering:
- Indication: ≥2 attacks/year, nephrolithiasis, tophi, uric acid >12 mg/dL
- Allopurinol (xanthine oxidase inhibitor) — start 100 mg/day after acute attack subsides, titrate to uric acid <6 mg/dL; adjust for CKD
- Febuxostat — alternative XO inhibitor
- Probenecid — uricosuric (only if underexcretor, normal renal function, no nephrolithiasis)
- Start colchicine prophylaxis 0.5 mg BID for 6 months when initiating allopurinol to prevent flare
5. Pseudogout (CPPD — Calcium Pyrophosphate Crystal Deposition Disease)
Definition & Pathogenesis
Pseudogout is acute CPP crystal arthritis — one presentation of CPPD. Calcium pyrophosphate dihydrate (CPP) crystals form in hyaline cartilage and fibrocartilage (not soft tissue like urate), then shed into the joint space. Degradation of cartilage proteoglycans (which normally inhibit mineralization) allows CPP crystallization around chondrocytes. CPP crystals activate the NLRP3 inflammasome (same as gout) → IL-1β → leukocyte recruitment.
Genetic links: Mutations in ANKH gene (inorganic pyrophosphate transporter) and OPG gene (RANKL decoy receptor).
Secondary causes (especially in young patients):
- Hyperparathyroidism
- Hemochromatosis
- Hypomagnesemia
- Hypothyroidism
- Hypophosphatasia (low alkaline phosphatase)
- Ochronosis, diabetes, prior joint trauma
Epidemiology
- Primarily elderly (>50 years); up to 60% of those ≥85 years affected
- Majority idiopathic
- Unlike gout: no strong sex predilection
CPPD Clinical Spectrum
| Subtype | Also Called |
|---|---|
| Asymptomatic CPPD | Chondrocalcinosis on imaging |
| Acute CPP crystal arthritis | Pseudogout |
| Chronic CPP inflammatory polyarthropathy | Pseudo-RA |
| OA with CPPD | Pseudo-OA |
Clinical Features
| Feature | Details |
|---|---|
| Joints | Knee most common, then wrist, elbow, shoulder, ankle |
| Attack character | Acute monoarthritis or oligoarthritis; less intense than gout; may last weeks to months |
| Chronic form | Persistent joint pain + acute flares resembling OA or RA |
| No tophi | (Unlike gout) |
Diagnosis
- Synovial fluid — definitive: rhomboid-shaped, weakly positively birefringent CPP crystals (blue when parallel to polarizer axis) — harder to detect than urate crystals
- WBC 15,000–30,000/mm³ during acute attack (neutrophilic)
- X-ray: chondrocalcinosis — calcification of menisci, triangular fibrocartilage complex (TFCC) of wrist, pubic symphysis — supportive but not diagnostic
- Hook-like osteophytes at MCPs (unlike RA, no typical bony erosions)
- Metabolic workup in young patients: calcium, PTH, iron/TIBC/ferritin, ALP, Mg²⁺
Treatment
- Acute: NSAIDs (first-line), intra-articular corticosteroids, oral corticosteroids, colchicine — same approach as gout
- Chronic: NSAIDs, low-dose colchicine, hydroxychloroquine, methotrexate for refractory cases
- No urate-lowering equivalent — no therapy proven to prevent or dissolve CPP crystals
- Treat underlying metabolic disease (though benefit on CPPD itself is unproven)
Key Comparison Table
| Feature | RA | OA | Reactive Arthritis | Gout | Pseudogout |
|---|---|---|---|---|---|
| Type | Autoimmune inflammatory | Degenerative | Post-infectious inflammatory | Crystal (MSU) | Crystal (CPP) |
| Age | 20–50 yr (peak) | >50 yr | 20–40 yr (young men) | 40–60 yr men | >50–60 yr |
| Sex | F:M 3:1 | F slight predominance | M:F 9:1 | M:F 7–9:1 | Equal |
| Joint pattern | Symmetric small joints (MCPs, PIPs, wrists) | Asymmetric DIPs, hips, knees | Asymmetric large joints (lower extremity) | Monoarticular; 1st MTP | Monoarticular; knee, wrist |
| Morning stiffness | ≥1 hour | <30 minutes | Variable | No (or minimal) | No |
| Onset | Insidious | Insidious | Acute (1–3 wk post-infection) | Sudden, nocturnal | Acute |
| Key serology | RF+, Anti-CCP+ | Negative | RF−, HLA-B27+ (50–80%) | Uric acid ↑ | Metabolic screen |
| Crystal | None | None | None | Needle, neg birefringent | Rhomboid, pos birefringent |
| X-ray findings | Erosions, periarticular osteopenia | Osteophytes, sclerosis, JSN | Sacroiliitis (asymmetric) | Punched-out erosions, tophi | Chondrocalcinosis |
| Hallmark finding | Pannus, symmetric synovitis | Cartilage fibrillation, eburnation | Dactylitis, enthesitis, keratoderma | Podagra, tophi, neg birefringent crystals | CPP crystals in cartilage |
| Synovial fluid | Inflammatory, no crystals | Non-inflammatory | Inflammatory, no crystals | Neg birefringent crystals | Pos birefringent crystals |
| Key treatment | MTX + biologics/JAKi | NSAIDs, PT, arthroplasty | NSAIDs + treat infection | NSAIDs/colchicine acute; allopurinol prophylaxis | NSAIDs/colchicine; no crystal-dissolving therapy |
| HLA association | HLA-DR4 | None | HLA-B27 | None | ANKH gene mutations |
Crystal Comparison: Gout vs. Pseudogout
| Property | Gout (MSU) | Pseudogout (CPP) |
|---|---|---|
| Crystal shape | Needle-shaped | Rhomboid (pleomorphic) |
| Birefringence | Strongly negative | Weakly positive |
| Color parallel to polarizer | Yellow | Blue |
| Location | Soft tissue, joint space | Cartilage (primary), then joint |
| X-ray | Punched-out erosions, tophi | Chondrocalcinosis |
| Common joint | 1st MTP | Knee, wrist |
| Treatment target | Uric acid (allopurinol/febuxostat) | Symptomatic only |
Sources: Textbook of Family Medicine 9e; Goldman-Cecil Medicine; Robbins, Cotran & Kumar Pathologic Basis of Disease; Washington Manual of Medical Therapeutics; Harrison's Principles of Internal Medicine 22E; Miller's Review of Orthopaedics 9th Edition.
This is a shared conversation. Sign in to Orris to start your own chat.